简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:The rupee is expected to average around 73.50-74 in FY22, as, despite a vaccine, the COVID-19 frenzy still persists and is likely to continue to grapple the foreign exchange market.
The rupee is expected to average around 73.50-74 in FY22, as, despite a vaccine, the COVID-19 frenzy still persists and is likely to continue to grapple the foreign exchange market.
The Indian rupee has registered more than 4% gain so far this fiscal year in the backdrop of sustained foreign fund inflows and the Reserve Bank of India's (RBI) dexterous policy manoeuvring, which ensured a solid year for the Indian currency, despite headwinds on the economic front, according to experts.
The pandemic-induced massive sell-off in the stock market led the rupee to breach a record low of 76.90.
However, the optimism over vaccines, easing of lockdown restrictions, infusion of stimulus by governments and central banks all over the world enthused investors with a general sense of optimism, and the rupee vaulted back to the 72 zone.
“Despite headwinds on the economic front and larger-than-anticipated fiscal deficit, the RBI's deft manoeuvring ensured lower yields for the G-secs and substantial accretion to forex (foreign exchange) reserves this year,” HDFC Securities Deputy Head (Retail Research) Devarsh Vakil told.
He added that the rupee is up by 4% against the US dollar for FY21 despite having much higher interest rates and inflation than the US.
Experts said sustained foreign fund inflows into India's listed stocks ensured a strong year for the Indian currency.
For the current financial year, foreign investors have poured in $35.22 billion, the biggest inflow since 2014-15. India has attracted the highest-ever foreign direct investment (FDI) inflows at $67.54 billion during the first nine months of the financial year 2020-21.
Stay tuned as WikiFX will bring you more Markets & Finance news!
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.